Etoposide in malignant pleural mesothelioma: Two phase II trials of the EORTC lung cancer cooperative group

Intravenous and oral etoposide (VP 16-213) were tested in two sequential phase II trials in chemotherapy-naive patients with malignant pleural mesothelioma. In the first trial, etoposide was given intravenously (i.v.) at a dose of 150 mg/m 2 on days 1, 3 and 5 every 3 weeks. The second trial investi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 1997-11, Vol.33 (13), p.2211-2215
Hauptverfasser:	Sahmoud, T., Postmus, P.E., van Pottelsberghe, Ch, Mattson, K., Tammilehto, L., Splinter, T.A.W., Planting, A.S.T., Sutedja, T., van Pawel, J., van Zandwijk, N., Baas, P., Roozendaal, K.J., Schrijver, M., Kirkpatrick, A., Van Glabbeke, M., Ardizzoni, A., Giaccone, G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Antineoplastic agents Antineoplastic Agents, Phytogenic - adverse effects Antineoplastic Agents, Phytogenic - therapeutic use Biological and medical sciences Chemotherapy Drug Administration Schedule etoposide Etoposide - adverse effects Etoposide - therapeutic use Female Humans Infusions, Intravenous Male Medical sciences mesothelioma Mesothelioma - drug therapy Mesothelioma - pathology Middle Aged Pharmacology. Drug treatments phase II Pleural Neoplasms - drug therapy Pleural Neoplasms - pathology Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!